Therapeutic potential of peritoneal mononuclear phagocytes from peritoneal dialysis patients

腹膜透析患者腹膜单核吞噬细胞的治疗潜力

• 批准号: nhmrc : 1061785
• 负责人: Dr Yiping Wang
• 金额: $ 25.06万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/therapeutic-potential-peritoneal-dialysis-patients/454929
• 关键词: Therapeutic; potential; peritoneal; mononuclear; phagocytes

Mononuclear phagocytes (MP) are key cells which are now being used to treat various diseases. In Australia, more than 10 million end stage kidney disease(ESKD) patients are treated with chronic dialysis, and more than 20% of them are on peritoneal dialysis (PD). Each PD patient discards more than 20 million MP in dialysate daily. We will explore the possibility of using these MP to treat diseases including transplant rejection.

单核吞噬细胞是目前用于治疗各种疾病的关键细胞。在澳大利亚，超过1000万终末期肾病（ESKD）患者接受慢性透析治疗，其中超过20%的患者接受腹膜透析（PD）治疗。每个PD患者每天在透析液中丢弃超过2000万MP。我们将探索使用这些MP治疗包括移植排斥在内的疾病的可能性。